As per our report, the global epigenetics market size is predicted to grow from USD 11.55 Billion in 2024 to USD 32.59 Billion by 2032, showcasing a CAGR of 13.84 % during the forecast period.
Epigenetics is the study of how changes in gene expression occur rather than changes in an organism's genetic makeup. There are companies and organizations that offer products and services related to the research of epigenetics, including tools for epigenetic editing, kits for detecting epigenetic biomarkers, and services for the detection of DNA methylation and histone modification. The study of epigenetics is important because it enables researchers to investigate the relationships between diseases and their causes and effects, illuminates the ways that a person's eating habits can affect their appearance, and pinpoints markers and mechanisms that can be used for diagnosis, prevention, and therapy. Epigenetics can be used to diagnose a person's kind of cancer or to find hard-to-find cancers sooner.
The growing cancer patient population worldwide majorly propels the global epigenetics market growth. The number of cancer cases is on the rise worldwide. WHO says low-income and middle-income countries have been affected the most and have been responsible for around 70% of fatalities all over the world. With an increase in the number of people suffering from these diseases also comes an increase in the demand for epigenetic research and diagnostic tools as the epigenetics study has revealed more approaches to cancer treatment. Diseases such as cancer and cardiovascular diseases are becoming increasingly common today; as a result, there has been an increase in demand in the epigenetics market.
The rising emphasis on personalized medicine, advancements in technology and tools for epigenetic analysis, increasing government funding and support for epigenetics research, rising demand for targeted and efficient therapeutics and growing awareness about the potential of epigenetic modifications in disease prevention and treatment drive the epigenetics market growth. The growing research on the role of epigenetics in aging and age-related diseases and the increasing application of epigenetics in non-invasive prenatal testing boost the growth rate of the epigenetics market.
In addition, the growing investments by pharmaceutical and biotech companies in epigenetic research and drug development, technological advancements in sequencing and genomics and rising demand for epigenetic biomarkers for early detection and diagnosis of diseases propel the epigenetics market growth. The growing adoption of epigenetic-based diagnostics for various diseases, the rising use of epigenetic analysis in drug discovery and development, the increasing importance of epigenetics in agriculture and animal breeding and the growing demand for epigenetic research in neuroscience and mental health boost the market’s growth rate. Furthermore, factors such as the rising adoption of epigenetic research in environmental science and toxicology, the increasing number of advancements in gene editing technology and its potential applications in epigenetics, the increasing application of epigenetics in the study of rare diseases and disorders, growing use of epigenetic therapies in combination with other treatments and rising interest in epigenetics among academic and research institutions fuel the epigenetics market growth.
Poor awareness about epigenetics and its potential benefits in some countries and the high cost of epigenetic analysis and diagnostic tests majorly hamper the epigenetics market growth. In addition, factors such as limited reimbursement policies for epigenetic tests and therapies, lack of standardization in epigenetic analysis and interpretation of results, regulatory challenges in the approval of epigenetic therapies, limited availability of skilled professionals in epigenetic research and analysis, challenges in obtaining high-quality DNA samples for epigenetic analysis and complexity of epigenetic data analysis and interpretation inhibit the market growth. Furthermore, a limited understanding of the epigenetic mechanisms involved in various diseases and ethical concerns related to epigenetic modifications and their potential effects on future generations impedes the market growth.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2032 |
Base Year |
2023 |
Forecast Period |
2024 to 2032 |
Segments Analysed |
By Anatomical Location, Consumable Type, and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter’s Five Forces Analysis; Competitive Landscape, Analyst Overview of Investment Opportunities |
Regions Analysed |
North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa |
Market Leaders Profiled |
Abcam PLC, Illumina, Inc., QIAGEN N.V., Merck & Co, New England Biolabs, Inc., Sigma-Aldrich Corporation, Thermo Fisher Scientific |
Based on product, the enzymes segment held the highest share of the global in 2023 and the segmental domination is expected to continue throughout the forecast period. The growing demand for enzymes for epigenetic research and analysis and the increasing application of enzymes in DNA methylation and histone modification analysis propel segmental growth. The growing adoption of enzymes in epigenetic drug discovery and development and technological advancements in enzyme engineering and optimization further contribute to segmental growth.
The instruments & consumables segment accounted for the second largest share of the global epigenetics market in 2023 and is expected to grow at a healthy CAGR during the forecast period owing to the advancements in technology and automation for efficient and accurate epigenetic analysis and growing demand for high-throughput epigenetic analysis systems. Increasing adoption of epigenetic analysis in clinical diagnostics and personalized medicine and growing demand for consumables such as DNA extraction kits, PCR reagents, and sequencing kits further boost the growth rate of the segment.
However, the kits segment is projected to grow at a notable CAGR over the forecast period due to factors such as the rising demand for easy-to-use and standardized epigenetic analysis kits and the growing use of epigenetic analysis in disease diagnosis and treatment.
Based on the research area, the oncology segment led the global epigenetics market in 2023 and the segment’s domination is expected to continue during the forecast period. The rising prevalence of cancer and the need for targeted and personalized cancer therapies, increasing research on the role of epigenetic modifications in cancer development and progression, growing adoption of epigenetic analysis in cancer diagnosis and prognosis and rising emphasis on epigenetic-based cancer therapies and drug development propel the segmental growth.
The developmental biology segment is expected to shine well in the epigenetics market during the forecast period. The growing research on the role of epigenetics in embryonic development and differentiation and the rising adoption of epigenetic analysis in stem cell research and regenerative medicine boost segmental growth. The growing number of advancements in epigenetic editing technology for gene therapy and disease modeling and the rising focus on epigenetic modifications in neurodevelopmental disorders drive segmental growth.
Based on enzymes, the DNA-Modifying Enzymes segment accounted for the majority of the share of the global epigenetics market in 2023.
On the other hand, the protein-modifying enzymes segment is predicted to account for a considerable share of the worldwide market during the forecast period.
The RNA-modifying enzymes segment is expected to have the highest CAGR in the coming years.
The qPCR segment was the market leader among different types of instruments and consumables in 2023 and is expected to continue dominating the market during the forecast period owing to the growing awareness through campaigns and digital platforms in the medical sector.
On the other hand, the next-generation sequences segment is expected to grow at a notable CAGR during the forecast period owing to the increasing number of studies on genomics.
The mass spectrometers and sonicators segments are predicted to have a prominent growth rate over the forecast period.
Based on KITS, the Bisulfate conversion kits segment is expected to lead the epigenetics market during the forecast period. In addition, public and private organizations are also investing in the biotechnology field, propelling segmental growth.
The Chip sequence kits, and RNA sequencing kits segments are anticipated to grow substantially during the forecast period owing to the growing demand to promote high-quality patient services.
The Whole-genome amplification kits and 5-HMC and 5-MC Analysis KITS segments are inclined to have the highest growth rate in a few years.
Based on reagents, the antibodies reagents segment is predicted to occupy the most significant share of the worldwide market during the forecast period.
On the other hand, segments such as buffers and histones are expected to lead the epigenetics market, accounting for a considerable share during the forecast period.
Based on the region, North America dominated the market for epigenetics worldwide in 2023 and the regional domination is predicted to continue throughout the forecast period. The presence of a well-established healthcare industry and research infrastructure, the rising prevalence of cancer and neurodegenerative diseases and increasing emphasis on precision medicine and personalized healthcare is leading to increased adoption of epigenetic analysis majorly driving the North American epigenetics market growth. Favorable reimbursement policies and government funding for research and development and the presence of key market players such as Thermo Fisher Scientific, Illumina and Qiagen contribute to the growth of the North American market. The U.S. accounted for close to 80% of the North American market in 2023 and is expected to be the largest segment in the North American market throughout the forecast period.
The European epigenetics market is expected to have promising growth in the coming years. Factors such as strong research infrastructure and focus on biotechnology and pharmaceuticals, growing focus on aging-related diseases such as Alzheimer's and Parkinson's and increasing adoption of epigenetic-based cancer therapies and drug development boost the growth rate of the European market. The presence of key market players such as Merck KGaA, Abcam, and Active Motif and the rising trend towards personalized medicine and targeted therapies are driving the adoption of epigenetic analysis and propelling the European market growth. Germany accounted for approximately 30% of the European market in 2023 and is expected to register healthy growth during the forecast period due to the rising prevalence of aging-related diseases, such as Alzheimer's and Parkinson's, and the growing trend toward personalized medicine in Germany.
The Asia-pacific epigenetics market is expected to grow at the highest CAGR during the forecast period. The presence of a large patient pool and increasing investment in healthcare infrastructure and research and development, rising adoption of precision medicine and personalized healthcare are driving the demand for epigenetic analysis and an increasing number of advancements in epigenetic research and analysis technology primarily contribute to the APAC market growth. The rising emphasis on agricultural and animal breeding applications of epigenetics and the presence of key market players such as Zymo Research, Diagenode, and Bio-Rad Laboratories further fuel the growth rate of the APAC market.
The Latin American epigenetics market is estimated to grow at a considerable share of the global market during the forecast period. The growing number of improvements in the healthcare infrastructure and research capabilities across the Latin American region, rising prevalence of chronic diseases such as cancer and diabetes and increasing emphasis on personalized medicine and targeted therapies drive the Latin American market growth.
The epigenetics market in MEA is anticipated to occupy a moderate share of the worldwide market in the coming years.
Companies playing a leading role in the global epigenetics market profiled in this report are Abcam PLC, Illumina, Inc., QIAGEN N.V., Merck & Co, New England Biolabs, Inc., Sigma-Aldrich Corporation, Thermo Fisher Scientific, Inc., Active Motif, Diagenode, Inc. and Zymo Research Corporation.
In March 2023, UCSF researchers uncovered a fresh method by which epigenetic alterations control the expression of certain genes in cancer cells. They discovered that the "molecular glue" protein KDM2B controls the expression of genes in cancer cells by adhering to chromatin.
In August 2021, a new epigenetic regulator named ZFP516 was discovered by University of Pennsylvania researchers, according to a study that was published in the journal Nature. They discovered that ZFP516 is essential for the growth of brown fat, a form of fat that can be used to cure obesity and burn calories.
By Product
By Research Area
By Enzymes
By Instruments & Consumables
By KITS
By Reagents
By Region
Frequently Asked Questions
As per our research report, the global epigenetics market size is projected to be USD 32.59 billion by 2032.
Yes, we have studied and included the COVID-19 impact on the global epigenetics market in this report.
Geographically, the North American epigenetics market accounted for the largest share of the global market in 2023.
The global epigenetics market is estimated to grow at a CAGR of 13.84% from 2024 to 2032.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region